Zhang Yi, Lin Shibu, Yang Xianjin, Zhang Xu
Department of General Surgery, the First People's Hospital of Neijiang, Neijiang 641000, Sichuan Province, P. R. China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Hainan, Medical College, Haikou 570102, Hainan Province, P. R. China.
J Cancer. 2019 Feb 26;10(6):1503-1510. doi: 10.7150/jca.28541. eCollection 2019.
LncRNA associated with microvascular invasion in hepatocellular carcinoma (lncRNA MVIH) is a newly discovered long non-coding RNA that aberrantly up-regulates and holds prognostic value in various tumors. The aim of the review and meta-analysis is to assess its prognostic potential and functions in malignant tumors. PubMed, PMC, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Database were carefully searched for articles published as of Jan. 1, 2018. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to demonstrate prognostic value of lncRNA MVIH using Stata 12.0 software. Six original studies including 830 cancer patients were ultimately enrolled in this meta-analysis. The pooled results showed that elevated lncRNA MVIH expression was significantly correlated with unfavorable OS (HR=2.17, 95% CI: 1.58-2.76, < 0.001) and RFS/DFS/PFS (HR=2.21, 95% CI: 1.54-2.87, < 0.001) in cancer patients. Additionally, high expression of lncRNA MVIH was related to positive lymph node metastasis (OR = 3.04, 95% CI: 1.37-6.75, = 0.006) and advanced clinical stage (OR = 2.52, 95% CI: 1.68-3.79, < 0.001). LncRNA MVIH over-expression was associated with poor clinical outcomes in multiple cancer types. More studies are warranted to verify and strengthen the clinical value of lncRNA MVIH in human cancers.
与肝细胞癌微血管侵犯相关的长链非编码RNA（lncRNA MVIH）是一种新发现的长链非编码RNA，在多种肿瘤中异常上调并具有预后价值。本综述和荟萃分析的目的是评估其在恶性肿瘤中的预后潜力和功能。我们仔细检索了PubMed、PMC、EMBASE、Web of Science、Cochrane图书馆、中国知网（CNKI）和万方数据库，以查找截至2018年1月1日发表的文章。使用Stata 12.0软件计算风险比（HRs）或比值比（ORs）及95%置信区间（95% CIs），以证明lncRNA MVIH的预后价值。最终，六项纳入830例癌症患者的原始研究被纳入本荟萃分析。汇总结果显示，lncRNA MVIH表达升高与癌症患者不良总生存期（HR=2.17，95% CI：1.58 - 2.76，<0.001）和无复发生存期/无病生存期/进展无生存期（HR=2.21，95% CI：1.54 - 2.87，<0.001）显著相关。此外，lncRNA MVIH高表达与阳性淋巴结转移（OR = 3.04，95% CI：1.37 - 6.75，=0.006）和临床晚期（OR = 2.52，95% CI：1.68 - 3.79，<0.001）相关。lncRNA MVIH过表达与多种癌症类型的不良临床结局相关。需要更多研究来验证和强化lncRNA MVIH在人类癌症中的临床价值。
